Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats

Molecular and Cellular Biochemistry

Volumn 314, Issue 1-2, 2008, Pages 123-131

  Goyal, Bhoomika R ^a,b   Mesariya, Pravin ^a   Goyal, Ramesh K ^a   Mehta, Anita A ^a  

^a L M COLLEGE OF PHARMACY   (India)

^b NIRMA UNIVERSITY   (India)

Author keywords

Cardiac complications; Diabetes mellitus; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CHOLESTEROL; COLLAGEN; CREATINE KINASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTATE DEHYDROGENASE; LIPID; STREPTOZOCIN; TELMISARTAN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BRADYCARDIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; NONHUMAN; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HEART RATE; HYPERTROPHY, LEFT VENTRICULAR; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; STREPTOZOCIN;

RATTUS; RATTUS NORVEGICUS;

EID: 45449092358     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9772-y     Document Type: Article

References (52)

1. McGill HC Jr, McMahan CA (1998) Determinants of atherosclerosis in the young: Pathobiological determinants of atherosclerosis in youth (PDAY) research group. Am J Cardiol 82:30T-36T
2. Zhi YF, Johannes BP, Marwick JH (2004) Diabetic cardiomyopathy: evidences, mechanism and therapeutic implications. Endocr Rev 25(4):543-567
3. Arauz-Pacheco C, Parrott MA, Raskin P (2002) The treatment of hypertension in adult patients with diabetes. Diabetes Care 25:134-147
4. Higaki J, Baba S, Katsuya T, Katsuya T, Sato N, Ishikawa K, Mannami T, Ogata J, Ogihara T (2000) Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men. The Suita study. Circulation 101:2060-2065
5. Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355:637-645
6. Stoll M, Unger T (2001) Angiotensin and its AT 2 receptor: New insights into an old system. Regul Pept 99:175-182
7. Siragy HM (2002) Angiotensin receptor blockers: How important is selectivity? Am J Hypertens 15:1006-1014
8. Benedict CR, Francis GS, Shelton B et al for the SOLVD Investigators (1995) Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 75:1151-1157
9. Struthers AD (1995) Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16:103-106
10. Kjeldsen SE, Julius S (2004) Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 148:747-754
11. Kakuta H, Sudoh K, Sasamatsu M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor blockers. Int J Clin Pharm Res 25(1):41-46
12. Benson SC, Pershadsingh HA, Ho C, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ - modulating activity. Hypertension 43:993-1002
13. Takano H, Hasegawa H, Zou Y, Komuro I (2004) Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 10:2779-2786
14. Goebel M, Clemenz M, Unger T (2006) Effective treatment of hypertension by AT 1 receptor antagonism: The past and future of telmisartan. Expert Rev Cardiovasc Ther 4(5):615-620
15. Yamagishi S, Takeuchi M (2005) Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-g-inducing property. Med Hypotheses 64:476-478
16. Prockop DJ, Udenfriend S (1960) A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1(3):228-239
17. Umrani DN, Goyal RK (2002) Beneficial effects of fenoldopam treatment on renal functions in streptozotocin induced diabetic rats. Clin Exp Hypertens 24(3):207-219
18. Goyal RK (1999) Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens 21:167-179
19. Pershadsingh HA, Benson SC, Ho CI, Avery MA, Kurtz TW (2003) Identification of PPAR-activators that do not promote fluid retention and edema: Implications for treating insulin resistant hypertension and the metabolic syndrome. In: Proceedings of the endocrine society symposium on nuclear receptors in cardiovascular disease, hot topics in endocrinology. San Diego, CA, Abstract 29
20. Dahm K, Tikellis C, Reid CM, Johnston CI, Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463-473
21. Taskinen M (1992) Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41:12-17
22. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH (1993) Glycosylated low density lipoprotein is more sensitive to oxidation: Implications for the diabetic patient? Atherosclerosis 102:63-67
23. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL (1999) Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 84:1043-1049
24. Chen H, Li D, Sawamura T, Inoue K, Mehta JL (2000) Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: Modulation by losartan. Biochem Biophys Res Commun 276:1100-1104
25. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J (1999) Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 100:899-902
26. Kannel WB (1987) Metabolic risk factors for coronary heart disease in women. Perspective from the Framingham study. Am Heart J 114:413-419
27. Castelli WP (1986) The triglyceride issue: A view from Framingham. Am Heart J 287:413-419
28. Bhakdi S, Toprzewski M, Klouche M, Hemmes M (1999) Complement and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhance complement activation. Arterioscler Thromb Vasc Biol 19:2348-2354
29. de Beer FC, Hind CRK, Fox KM, Allan R, Maseri A, Pepys MB (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47:239-243
30. Rani SH, Rao DV, Prakash SM, Jyothy A (2003) Serum Adenosine deaminase activity and C-reactive protein levels in unstable angina. Indian J Human Genet 9(1):17-20
31. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, Eisenbarth GS, Rewers M (2004) Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 53:2569-2573
32. Pradhan A, Manson J, Rifai N, Buring J, Ridker P (2001) C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334
33. Yoshida S, Yamsgishi K, Nakamura T, Matsui T, Imaizumi M, Takeuchi H, Koga T, Ueno, Sata M (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferators activated receptor-β activation. Diabetologia 49(11):3094-3099
34. Howard-Alpe GM, Sear JW, Foex P (2006) Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers. Brit J Anaesth 97(6):758-769
35. Huang E, Kuo W, Chen Y, Chen T, Chang M, Lu M, Tzang B, Hsu H, Huang C, Lee S (2006) Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clinica Himica Acta 366(1-2):293-298
36. Hagar HH (2002) Folic acid and vitamin B 12 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol Res 46(3):213-219
37. Williamson JR, Kilo C (1976) Capillary basement membrane thickening and diabetic microangiopathy. Diabetes 25:925-927
38. Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care 2:120-126
39. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101:899-907
40. Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diDstolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105:1387-1393
41. Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT (1995) Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 76:80-130
42. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T (2006) Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol 41(6):989-997
43. Jesmin S, Sakuma I, Hattori Y, Kitabatake A (2003) Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol 23:2021-2026
44. Gorden T, Kannel WB (1971) Premature mortality from coronary heart disease. The Framingham study. JAMA 215:1617-1625
45. Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T (1992) Left ventricular mass in diabetes. Arch Int Med 152:5
46. Sun Y, Zhang JQ, Zhang J, Ramires FJ (1995) Angiotensin II, transforming growth factor-β 1 and repair in the infarcted heart. J Mol Cell Cardiol 30:1559-1569
47. Smits JFM, Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP (1992) Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 20:772-778
48. Funakawa S (1983) Renin angiotensin system and prostacyclin biosynthesis in STZ diabetic rats. Eur J Pharmacl 94:27-33
49. Goebel M, Clemenz M, Unger T (2006) Effective treatment of hypertension by AT 1 receptor antagonism: The past and future of telmisartan. Expert Rev Cardiovasc Ther 4(5):615-620
50. Savarese JJ, Berkowitz BA (1979) Beta adrenergic receptors decrease in diabetic rat hearts. Life Sci 25:2075-2078
51. Ferrario CM, Ueno Y, Diz DJ, Bannes KL (1986) The renin-angiotensin system: Physiological actions on the central nervous system. In: Zanchetti A, Tarazi C (eds) Handbook of hypertension, vol. 8. Elsevier Science Publishers, Amsterdam, the Netherlands, pp 431-454
52. Oliveira DR, Santos RA, Santos GF, Khosla MC, Campagnole-Santos MJ (1996) Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension 27:1284-1290